One such study is the phase III ALINA trial studying adjuvant alectinib in comparison to chemotherapy (CT) alone in patients with completely resected stage IB-IIIA (N2 stage) ALK positive NSCLC [100]. This evidence concerns the gene ALK and non-small cell lung carcinoma.